1223P First-line lenvatinib (Len) + pembrolizumab (Pembro) + chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in
K. Shitara(National Cancer Center Hospital East), Irit Ben‐Aharon(Rambam Health Care Campus), C. Rojas, D.A. Acosta Eyzaguirre(Hebron University), Ayala Hubert(Hebrew University of Jerusalem), H. Araya Moya(Catholic University of the Maule), Deirdre Jill Cohen(Icahn School of Medicine at Mount Sinai), L-Y. Bai(China Medical University), François Ghiringhelli(Centre Georges François Leclerc), L. Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Y. Y. Janjigian(Memorial Sloan Kettering Cancer Center), J. Tabernero(Vall d'Hebron Hospital Universitari), E. Van Cutsem(KU Leuven), Shu-Kui Qin(Nanjing University of Chinese Medicine), Jieting Xu(Chinese PLA General Hospital), A. Wang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mary Gwen Miller(Merck & Co., Inc., Rahway, NJ, USA (United States)), C-S. Shih(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pooja Bhagia(Merck & Co., Inc., Rahway, NJ, USA (United States)), P.E. Yanez Weber(Universidad de La Frontera)
Cited by 5
Abstract
Related Papers
No related papers found
Powered by citation graph analysis